Personalis (PSNL) Stock
Genomics services firm for cancer research partners. Here's the price, business snapshot, and what's worth knowing about Personalis in July 2026.
Personalis, Inc. (PSNL) is a clinical‑stage genomics company that provides advanced DNA sequencing, bioinformatics and immune profiling services used in oncology research and personalised cancer programmes. Its offerings include tumour–normal sequencing, neoantigen discovery, and adaptive immune receptor profiling, sold to biopharma partners and research institutions. Investors should know Personalis primarily earns revenue from service contracts and collaborations rather than marketed therapeutics, so growth depends on partner adoption and demand for precision oncology tools. As a small‑cap biotechnology firm (market cap ≈ $848.64M), PSNL can offer upside if its assays and proprietary analytics gain broader uptake, but it also carries typical sector risks: funding needs, competition, reimbursement and regulatory uncertainty. Financial performance can be variable and future profitability is not guaranteed. This is general educational information and not personalised investment advice; consider your risk tolerance and review the company’s filings or consult a financial adviser before investing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying PERSONALIS INC stock, expecting its value to rise significantly.
Financial Health
PERSONALIS INC is generating modest revenue and cash flow, but faces low profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PSNL
Pharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: 11 August 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: 27 July 2025
Explore BasketLiquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: 17 June 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision Oncology Services
Demand for personalised cancer diagnostics and neoantigen discovery could drive revenue growth, though uptake and timing can vary and affect returns.
Proprietary Analytics Edge
Personalis’s bioinformatics and IP may differentiate its offering, but technological competition and execution risk remain important considerations.
Partner‑Led Growth
Revenue is often driven by collaborations with pharma and research centres, so progress depends on partner pipelines and commercial adoption.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
